EP Regimen

EP Regimen

Drugs:

• Etoposide (E) – topoisomerase II inhibitor
• Cisplatin (P) – platinum compound

Common Uses

• Small Cell Lung Cancer (SCLC) – standard of care, often with concurrent or sequential radiation in limited-stage disease.
• Germ Cell Tumors (testicular cancer) – alternative to BEP when bleomycin is contraindicated (e.g., pulmonary issues).
• Sometimes used in other solid tumors (e.g., ovarian, cervical, neuroendocrine tumors).

Dosing Examples (varies by protocol)

• SCLC (21-day cycle):
  • Cisplatin 75 mg/m² IV day 1
  • Etoposide 100 mg/m² IV days 1–3
• Testicular Cancer (EP x 4 cycles if bleomycin not used):
  • Cisplatin 20 mg/m² IV days 1–5
  • Etoposide 100 mg/m² IV days 1–5

Toxicities

• Myelosuppression (especially neutropenia, thrombocytopenia)
• Nausea & vomiting (cisplatin is highly emetogenic)
• Nephrotoxicity (cisplatin → hydration and antiemetics required)
• Ototoxicity (cisplatin)
• Peripheral neuropathy (cisplatin, cumulative)
• Mucositis, alopecia (etoposide)

Key Clinical Notes for Oncology Pharmacist

• Hydration is essential with cisplatin (to reduce nephrotoxicity).
• Monitor renal function, electrolytes (Mg, K).
• Monitor CBC closely (risk of neutropenia).
• Alternative: Carboplatin + etoposide (often used in extensive-stage SCLC, esp. if cisplatin not tolerated).

Summary:

EP = Etoposide + Cisplatin, used mainly in SCLC and testicular cancer, with dose-limiting toxicities of myelosuppression and cisplatin-related nephrotoxicity.